MUC1-EGFR crosstalk with IL-6 by activating NF-κB and MAPK pathways to regulate the stemness and paclitaxel-resistance of lung adenocarcinoma

References

• Nasim F, Sabath BF, Eapen GA. Lung cancer. Med Clin North Am. 2019;103(3):1–15. doi: 10.1016/j.mcna.2018.12.006.
   PubMed Web of Science ®Google Scholar
• Cufer T, Ovcaricek T, O’Brien ME. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer. 2013;49(6):1216–1225. doi: 10.1016/j.ejca.2012.11.021.
   PubMed Web of Science ®Google Scholar
• Nagy-Mignotte H, Guillem P, Vesin A, et al. Primary lung adenocarcinoma: characteristics by smoking habit and sex. Eur Respir J. 2011;38(6):1412–1419. doi: 10.1183/09031936.00191710.
   PubMed Web of Science ®Google Scholar
• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300. doi: 10.21037/tlcr.2016.06.07.
   PubMed Web of Science ®Google Scholar
• Orr GA, Verdier-Pinard P, McDaid H, et al. Mechanisms of taxol resistance related to microtubules. Oncogene. 2003;22(47):7280–7295. doi: 10.1038/sj.onc.1206934.
   PubMed Web of Science ®Google Scholar
• Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 2018;9(2):117. doi: 10.1038/s41419-017-0063-y.
   PubMed Web of Science ®Google Scholar
• Steinbichler TB, Dudás J, Skvortsov S, et al. Therapy resistance mediated by cancer stem cells. Semin Cancer Biol. 2018;53:156–167. doi: 10.1016/j.semcancer.2018.11.006.
   PubMed Web of Science ®Google Scholar
• Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond). 2012;7(4):597–615. doi: 10.2217/nnm.12.22.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang Z, Ajani JA, et al. Drug resistance and cancer stem cells. Cell Commun Signal. 2021;19(1):19. doi: 10.1186/s12964-020-00627-5.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Dong Q, Li J, et al. Targeting cancer stem cells and their niche: perspectives for future therapeutic targets and strategies. Semin Cancer Biol. 2018;53:139–155. doi: 10.1016/j.semcancer.2018.08.002.
   PubMed Web of Science ®Google Scholar
• Lv Y, Cang W, Li Q, et al. Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer. Oncogenesis. 2019;8(12):70. doi: 10.1038/s41389-019-0179-2.
   PubMedGoogle Scholar
• Chen W, Zhang Z, Zhang S, et al. MUC1: structure, function, and clinic application in epithelial cancers. Int J Mol Sci. 2021;22(12):6567. doi: 10.3390/ijms22126567.
   Web of Science ®Google Scholar
• Kashyap B, Kullaa AM. Regulation of mucin 1 expression and its relationship with oral diseases. Arch Oral Biol. 2020seq;117:104791. doi: 10.1016/j.archoralbio.2020.104791.
   PubMed Web of Science ®Google Scholar
• Gao T, Cen Q, Lei H. A review on development of MUC1-based cancer vaccine. Biomed Pharmacother. 2020 Dec;132:110888. doi: 10.1016/j.biopha.2020.110888.
   PubMed Web of Science ®Google Scholar
• Johansson ME, Sjövall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol. 2013;10(6):352–361. doi: 10.1038/nrgastro.2013.35.
   PubMed Web of Science ®Google Scholar
• Cascio S, Finn OJ. Intra- and extra-cellular events related to altered glycosylation of MUC1 promote chronic inflammation, tumor progression, invasion, and metastasis. Biomolecules. 2016;6(4):39. doi: 10.3390/biom6040039.
   PubMed Web of Science ®Google Scholar
• Jin W, Liao X, Lv Y, et al. MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner. Cell Death Dis. 2017;8(8):e2980–e2980. doi: 10.1038/cddis.2017.378.
   PubMed Web of Science ®Google Scholar
• Xu H, Gao H, Li H, et al. Downregulated mucin 1 alleviates paclitaxel resistance in non‑small cell lung cancer cells. Mol Med Rep. 2020;22(4):2966–2972. doi: 10.3892/mmr.2020.11349.
   PubMed Web of Science ®Google Scholar
• Bouillez A, Adeegbe D, Jin C, et al. MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. Oncoimmunology. 2017;6(9):e1338998. doi: 10.1080/2162402x.2017.1338998.
   PubMed Web of Science ®Google Scholar
• Smith AG, Macleod KF. Autophagy, cancer stem cells and drug resistance. J Pathol. 2019;247(5):708–718. doi: 10.1002/path.5222.
   PubMed Web of Science ®Google Scholar
• Jin W, Zhang M, Dong C, et al. The multifaceted role of MUC1 in tumor therapy resistance. Clin Exp Med. 2022;23(5):1441–1474. doi: 10.1007/s10238-022-00978-y.
   PubMedGoogle Scholar
• Joshi S, Kumar S, Bafna S, et al. Genetically engineered mucin mouse models for inflammation and cancer. Cancer Metastasis Rev. 2015;34(4):593–609. doi: 10.1007/s10555-015-9549-1.
   PubMed Web of Science ®Google Scholar
• Schroeder JA, Thompson MC, Gardner MM, et al. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem. 2001;276(16):13057–13064. doi: 10.1074/jbc.M011248200.
   PubMed Web of Science ®Google Scholar
• Gebregiworgis T, Purohit V, Shukla SK, et al. Glucose limitation alters glutamine metabolism in MUC1-Overexpressing pancreatic cancer cells. J Proteome Res. 2017;16(10):3536–3546. doi: 10.1021/acs.jproteome.7b00246.
   PubMed Web of Science ®Google Scholar
• Inagaki Y, Gao J, Song P, et al. Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer. World J Gastroenterol. 2014;20(20):6123–6132. doi: 10.3748/wjg.v20.i20.6123.
   PubMed Web of Science ®Google Scholar
• Duraisamy S, Ramasamy S, Kharbanda S, et al. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 and MUC16. Gene. 2006;373:28–34. doi: 10.1016/j.gene.2005.12.021.
   PubMed Web of Science ®Google Scholar
• Ahmad R, Raina D, Trivedi V, et al. MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling. Nat Cell Biol. 2007;9(12):1419–1427. doi: 10.1038/ncb1661.
   PubMed Web of Science ®Google Scholar
• Situ D, Wang J, Ma Y, et al. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol. 2011;28 Suppl 1: s596–604. doi: 10.1007/s12032-010-9752-4.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Kishimoto H, Kobayashi H, et al. The glycosylated N-Terminal domain of MUC1 is involved in chemoresistance by modulating drug permeation across the plasma membrane. Mol Pharmacol. 2023;103(3):166–175. doi: 10.1124/molpharm.122.000597.
   PubMed Web of Science ®Google Scholar
• Bouillez A, Rajabi H, Jin C, et al. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene. 2017;36(28):4037–4046. doi: 10.1038/onc.2017.47.
   PubMed Web of Science ®Google Scholar
• Ham SY, Kwon T, Bak Y, et al. Mucin 1-mediated chemo-resistance in lung cancer cells. Oncogenesis. 2016;5(1):e185–e185. doi: 10.1038/oncsis.2015.47.
   PubMedGoogle Scholar
• Sousa AM, Rei M, Freitas R, et al. Effect of MUC1/β-catenin interaction on the tumorigenic capacity of pancreatic CD133(+) cells. Oncol Lett. 2016;12(3):1811–1817. doi: 10.3892/ol.2016.4888.
   PubMed Web of Science ®Google Scholar
• Wang S, Xu ZY, Wang LF, et al. CD133+ cancer stem cells in lung cancer. Front Biosci (Landmark Ed). 2013;18(2):447–453. doi: 10.2741/4113.
   PubMedGoogle Scholar
• Korkaya H, Kim GI, Davis A, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012;47(4):570–584. doi: 10.1016/j.molcel.2012.06.014.
   PubMed Web of Science ®Google Scholar
• Grubelnik G, Boštjančič E, Pavlič A, et al. NANOG expression in human development and cancerogenesis. Exp Biol Med (Maywood). 2020;245(5):456–464. doi: 10.1177/1535370220905560.
   PubMed Web of Science ®Google Scholar
• Mohiuddin IS, Wei SJ, Kang MH. Role of OCT4 in cancer stem-like cells and chemotherapy resistance. Biochim Biophys Acta Mol Basis Dis. 2020;1866(4):165432. doi: 10.1016/j.bbadis.2019.03.005.
   PubMed Web of Science ®Google Scholar
• Mirzaei S, Paskeh MDA, Entezari M, et al. SOX2 function in cancers: association with growth, invasion, stemness and therapy response. Biomed Pharmacother. 2022;156:113860. doi: 10.1016/j.biopha.2022.113860.
   PubMed Web of Science ®Google Scholar
• Huang Y, Sadée W. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett. 2006;239(2):168–182. doi: 10.1016/j.canlet.2005.07.032.
   PubMed Web of Science ®Google Scholar
• Shimomura M, Yaoi T, Itoh K, et al. Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines. Int J Oncol. 2012;40(4):995–1004. doi: 10.3892/ijo.2011.1297.
   PubMed Web of Science ®Google Scholar
• Butti R, Das S, Gunasekaran VP, et al. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol Cancer. 2018;17(1):34. doi: 10.1186/s12943-018-0797-x.
   PubMedGoogle Scholar
• Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 2009;1(5):a000141–a000141. doi: 10.1101/cshperspect.a000141.
   PubMed Web of Science ®Google Scholar
• Zakaria N, Mohd Yusoff N, Zakaria Z, et al. Inhibition of NF-κB signaling reduces the stemness characteristics of lung cancer stem cells. Front Oncol. 2018;8:166. doi: 10.3389/fonc.2018.00166.
   PubMed Web of Science ®Google Scholar
• Alam M, Rajabi H, Ahmad R, et al. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget. 2014;5(9):2622–2634. doi: 10.18632/oncotarget.1848.
   PubMedGoogle Scholar
• Ahmad R, Raina D, Joshi MD, et al. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res. 2009;69(17):7013–7021. doi: 10.1158/0008-5472.Can-09-0523.
   PubMed Web of Science ®Google Scholar
• Ibrahim SA, Gadalla R, El-Ghonaimy EA, et al. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, notch and EGFR signaling pathways. Mol Cancer. 2017;16(1):57. doi: 10.1186/s12943-017-0621-z.
   PubMed Web of Science ®Google Scholar
• Hosseinzadeh A, Merikhian P, Naseri N, et al. MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy. Cancer Cell Int. 2022;22(1):110. doi: 10.1186/s12935-022-02523-z.
   PubMed Web of Science ®Google Scholar
• Seumois G, Ramírez-Suástegui C, Schmiedel BJ, et al. Single-cell transcriptomic analysis of allergen-specific T cells in allergy and asthma. Sci Immunol. 2020;5(48):eaba6087. doi: 10.1126/sciimmunol.aba6087.
   PubMed Web of Science ®Google Scholar
• Li S, Wang H, Ma R, et al. Schisandrin B inhibits epithelial‑mesenchymal transition and stemness of large‑cell lung cancer cells and tumorigenesis in xenografts via inhibiting the NF‑κB and p38 MAPK signaling pathways. Oncol Rep. 2021;45(6):115. doi: 10.3892/or.2021.8066.
   Web of Science ®Google Scholar